BCYPU - SAB Biotherapeutics to list on Nasdaq through merger with Big Cypress Acquisition

SAB Biotherapeutics a clinical-stage biopharmaceutical announces definitive merger agreement with Big Cypress Acquisition Corp. (BCYP) a blank check company focused on innovative biopharmaceutical firms; the combined company will be listed on NASDAQ.SAB-185–a novel government-funded therapeutic for COVID-19–moved from concept to the clinic in just 128 days and has the potential to effectively address emerging variants.The proposed transaction implies an enterprise value for SAB, on a post-merger basis, of ~$325M (assuming a share price of $10.10 per share) and is expected to provide the combined company with ~$118M of pro forma cash to fuel development and commercialization of SAB’s unique DiversitAb™ platform that leverages its proprietary transchromosomic (Tc) bovine™ herds to produce highly-potent targeted fully-human polyclonal antibody therapeutics.The combined company will operate as SAB Biotherapeutics and will continue to operate under the SAB management team, with Big Cypress Acquisition Corp.’s Samuel J. Reich and Jeffrey G. Spragens joining the SAB Board

For further details see:

SAB Biotherapeutics to list on Nasdaq through merger with Big Cypress Acquisition